BMS is actively litigating to protect its top-selling product, Eliquis ($4.1B quarterly revenue), from generic competition in the U.S. and Europe. This high-stakes legal battle consumes significant resources and highlights the immense financial risk the company faces from patent expiry and challenges.
Filing excerpt
Following the May 2021 expiration of regulatory exclusivity for Eliquis in Europe, generic manufacturers have sought to challenge our Eliquis patents... which has led to the filing of infringement and invalidity actions involving our Eliquis patents...
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
Regions named
sec-10qlitigationMaterialGet every 10-Q signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/a743dc26-f2b6-4824-921d-cbef3a8c501a returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "a743dc26-f2b6-4824-921d-cbef3a8c501a",
"signal_type": "sec-10q",
"signal_subtype": "litigationMaterial",
"detected_at": "2026-05-05T08:48:21.337+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "BMS is actively litigating to protect its top-selling product, Eliquis ($4.1B quarterly revenue), from generic competition in the U.S. and Europe. This high-stakes legal battle consumes significant resources and highlights the immense financial risk the company faces from patent expiry and challenges.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Quarterly revenue of Eliquis, the drug being defended",
"dollar_millions": 4137
},
"summary": "Engaged in patent infringement lawsuits to defend blockbuster drug Eliquis from generics",
"excerpts": "Following the May 2021 expiration of regulatory exclusivity for Eliquis in Europe, generic manufacturers have sought to challenge our Eliquis patents... which has led to the filing of infringement and invalidity actions involving our Eliquis patents...",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000010/bmy-20260331.htm",
"filing_date": "2026-04-30",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Legal tech opportunity",
"signal_category": "risk",
"regions_mentioned": [
"United States",
"Europe"
],
"competitors_mentioned": [
"Pfizer"
]
}
}
curl https://signals.autobound.ai/v1/signals/a743dc26-f2b6-4824-921d-cbef3a8c501a \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.